New Dual-Action antibody enters early human trials for tough cancers
NCT ID NCT05357651
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This early-stage study is testing an experimental drug called LB1410 in people with advanced solid tumors or lymphoma that hasn't responded to standard treatments. The drug is a bispecific antibody designed to block two proteins (PD-1 and TIM-3) that can help cancer hide from the immune system. The main goals are to check if the drug is safe, what side effects it causes, and how the body processes it. About 100 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.